Navigation Links
Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
Date:2/4/2009

CALGARY, Feb. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) and the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA) announced a broad preclinical and clinical collaboration involving up to five, open-label, Phase 2 studies exploring the use of REOLYSIN(R) in combination with chemotherapy for various cancer indications. These indications are expected to include melanoma, pancreatic cancer, squamous cell lung, liver and K-RAS mutated colorectal cancers in combination with standard chemotherapeutics. This research program is in addition to Phase 2 trials in sarcoma and refractory head & neck cancers, sponsored by Oncolytics that are currently underway at this site.

"As an NCI-designated cancer center, we give a very high priority to approaches that are likely to significantly improve the prognosis of patients with malignant diseases," said Dr Giles, Deputy Director of the CTRC at UTHSCSA. "As Director of our Institute for Drug Development (IDD), I am pleased to specifically dedicate IDD resources toward the further rapid investigation of REOLYSIN(R), an agent which is proving itself in the clinic."

"We're excited that an institution of this caliber is investing in additional research opportunities for REOLYSIN(R)," said Dr. Karl Mettinger, Chief Medical Officer of Oncolytics. "This comprehensive research program will explore additional opportunities for REOLYSIN(R) in cancer treatment, while allowing the Company to focus its resources on developing its pivotal program."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

About CTRC at UTHSCSA

The CTRC at the UT Health Science Center serves more than 4.4 million people in the high-growth corridor of South and Central Texas, including San Antonio, Austin, Laredo and the Rio Grande Valley. It handles more than 120,000 patient visits each year. The mission of the CTRC at the UT Health Science Center is to promote interdisciplinary research in cancer-related areas of basic science, clinical research, and cancer prevention and control, and to foster the application of the results of that research in the community setting, especially in the South Texas community. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical research studies program in the world. In a Phase I research study, a new agent for cancer is tested in human patients for the first time. Fifteen of the cancer drugs most recently approved by the U.S. Food and Drug Administration underwent development or testing at the IDD.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the CTRC at UTHSCSA-sponsored trials, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. Information about CTRC at the UT Health Science Center was provided by CTRC. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. VIDEO from Medialink and International HIFU: New Prostate Cancer Procedure Being Tested in US Clinical Trials
2. Society of Gynecologic Oncologists 40th Annual Meeting on Womens Cancer to Include Sessions on Robotics Surgery
3. Winning the War on Cancer: The Critical Role of Radiation Oncology
4. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
5. Research Teams at J. Craig Venter Institute and Ludwig Institute for Cancer Research Uncover New Chromosomal Alterations in Cancer Using Transcriptome Sequencing Approach
6. Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
7. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
8. Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer
9. Chemoembolization Improving as Liver Cancer Treatment
10. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
11. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 2016 194 Mitgliedsstaaten ... Eliminierung von viraler Hepatitis    Am ... eingegangen, virale Hepatitis bis 2030 zu eliminieren. ... Assembly haben sich die Staaten einstimmig dafür entschieden, ... Viral Hepatitis Strategy) zu verabschieden, was das bisher ...
(Date:5/30/2016)... ALBANY, New York , May 30, 2016 /PRNewswire/ ... new market report titled, "Advanced (3D/4D) Visualization Systems Market ... Forecast 2016 - 2024." According to the report, the ... US$ 1.8 Bn in 2015 and is anticipated to ... 2024 to reach US$ 3.2 Bn in 2024. ...
(Date:5/30/2016)... According to a new ... by Type (Stability, Raw Materials, Method Validation, Microbial, ... Companies, Medical Device Companies) - Global Forecast to ... growth during the last decade and is expected ... 2016 and 2021 to reach USD 4.13 Billion ...
Breaking Medicine Technology:
(Date:5/31/2016)... Miami, FL (PRWEB) , ... May 31, 2016 , ... ... the wellness industry, today released ten predictions on the future of wellness, travel, spa ... CEOs of top travel, spa and beauty companies to leading economists and researchers - ...
(Date:5/31/2016)... ... May 31, 2016 , ... In his latest video, ... traits in humans. Using presidential candidate Donald Trump as an example, Kalsi describes ... “AstroNumerology is not about adding numbers up,” says Kalsi. “It is about looking ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... The Orthopaedic ... executive committee members: , David G. Lewallen, MD, began his term as president ... president. Michael L. Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, will ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Phynd Technologies, Inc. ... GA; Houston Methodist – Houston, TX and Shore Medical Center – Somers Point, NJ. ... three different, leading EHR solutions, demonstrating the breadth of Phynd’s solution and its interoperability. ...
(Date:5/31/2016)... ... ... In a recent interview on The Greenburgh Report radio show hosted by ... (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues ... , During the interview with Mr. Feiner that aired on May 7, 2016, ...
Breaking Medicine News(10 mins):